BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment.

Slides:

Advertisements

Similar presentations

Signals for T cell activation Costimulation and the B7:CD28 family

Advertisements

Cancer Immunotherapy Manipulation of co-stimulatory signals Enhancement of APC activity Cytokine therapy Monoclonal antibody therapy.

Basic Immunology University of Tabuk Faculty of Applied Medical Science Department of Medical Laboratory Technology Mr.AYMAN.S.YOUSIF MSc.Medical Microbiology.

Cancer Immunotherapy Presented by Md. Farhadur Rahman Phase A Student Department of Microbiology BSMMU.

Cancer immunotherapy: an update

ایمونولوژی سرطان پزشکی -آذرماه 1387.

Immunological tolerance and immune regulation -- 1

Immune Keytruda.

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Atezolizumab Drugbank ID : DB11595.

Suzanne L. Topalian, Charles G. Drake, Drew M. Pardoll Cancer Cell

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Karl S. Peggs, Neil H. Segal, James P. Allison Cancer Cell

Cancer and the Immune System

CELL-MEDIATED IMMUNITY RAHUL KUMAR LOHANA 2K16/MB/50 INSTITUTE OF MICROBIOLOGY UNIVERSITY OF SINDH, JAMSHORO.

Tumor Immunity: Exploring the Role of a Checkpoint

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Ertumaxomab Recombinant Anti-HER2 × Anti-CD3 Bispecific Antibody (Triomab), Expressed as an anti- HER2 scFv region fused with an anti-CD3 monoclonal antibody.

Figure 1 CTLA-4 and PD-1–PD-L1 immune checkpoints

by Jennifer Couzin-Frankel

Overview of next-generation sequencing, neoantigen prediction, and functional T-cell analyses. Overview of next-generation sequencing, neoantigen prediction,

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Immune Prophets of Lung Cancer: The Prognostic and Predictive Landscape of Cellular and Molecular Immune Markers Ivana Catacchio, Anna Scattone, Nicola.

Figure 1 Immunomodulatory monoclonal antibodies and armoured chimeric antigen receptor (CAR) T cells overcome immune suppression Figure 1 | Immunomodulatory.

Advances in Specific Immunotherapy for Prostate Cancer

Heating is a multifunctional adjuvant that affects tumor microenvironment through several intrinsic and extrinsic mechanisms, which could enhance immunotherapy.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Co-Receptors: Function

Schematic diagram outlining the antitumor activity and abscopal effect in combining checkpoint inhibitors with radiation-induced immune response. Schematic.

Nat. Rev. Gastroenterol. Hepatol. doi: /nrgastro

Antigen-induced regulatory T cells

Markers of cancer cell and lymphocytes in inflammatory infiltration around a tumour as potential markers of immunomodulatory treatment response. Markers.

CD30 and Lymphoma: Pathology in Practice

Figure 2 Co-stimulatory receptors as immunomodulatory targets

Rare cells predict GVHD

David P. Carbone, MD, PhD, David R. Gandara, MD, Scott J

Colorectal cancer vaccines: Principles, results, and perspectives

Cyclosporine in the Treatment of Dermatologic Disease: An Update

Cancer Immunotherapy Presented by Md. Farhadur Rahman Phase A Year II

Figure 1 The role of CTLA4 and PD1 in T cell activation

Potential mechanisms of therapeutic synergy between epigenetic modulation and PD-1 pathway blockade. Potential mechanisms of therapeutic synergy between.

Figure 2 Site of action of checkpoint inhibitors and agonists being

Robert J Korst, MD, Ronald G Crystal, MD

Targeted therapies in hematological malignancies using therapeutic monoclonal antibodies against Eph family receptors Sara Charmsaz, Andrew M. Scott,

Mechanism of CTLA-4-induced immunosuppression.

Tilo Biedermann, Martin Röcken, José M. Carballido

Nat. Rev. Endocrinol. doi: /nrendo

Schematic representation of mechanisms leading to the synergy of anti-CD137 and anti–PD-1 immunostimulatory mAbs. Schematic representation of mechanisms.

Tumor immunology.

Figure 1 Mechanisms of action of immunotherapy modalities

Volume 143, Issue 1, Pages (July 2012)

Tumor Immunology Ali Al Khader, MD Faculty of Medicine

Cell-mediated immunity Regulation of the immune response

Mechanism of PD-1/PD-L1 pathway-induced immunosuppression within the tumour microenvironment. Mechanism of PD-1/PD-L1 pathway-induced immunosuppression.

Distribution of immune checkpoint in tumor cells and immune microenvironment. CTLA-4, cytotoxic T lymphocyte antigen-4; MHC, major histocompatibility complex;

Releasing the Brakes on Cancer Immunotherapy

Vaccines for Lung Cancer

Dendritic-Cell-Based Therapeutic Cancer Vaccines

TSLP and Th2 Cells TSLP TSLP TSLP

by Jennifer Couzin-Frankel

Induction of cytotoxic activity in humanized SCC3 tumor-bearing mice treated with anti-PD-1 antibody. Induction of cytotoxic activity in humanized SCC3.

CDN–treated MOC1 tumors demonstrate enhanced activation of innate and antigen-specific adaptive immunity. CDN–treated MOC1 tumors demonstrate enhanced.

(A) Lymph node priming phase: recognition of major histocompatibility complex (MHC) by T-cell receptor (TCR), coactivating CD 28/B7 pathway activation.

Human cancer immunotherapy strategies targeting B7-H3 A, blockade of B7-H3 with blocking mAbs neutralizes inhibitory signaling in its unidentified receptor(s)

Specific reaction with MIB1, M30, and CD31 monoclonal antibodies in primary human cervical carcinoma before (A, C, and E) and after (B, D, and F) Tam treatment.

CTLA-4 and PD-1 modulate different aspects of the T-cell response: A, CTLA-4 is upregulated after antigen-specific activation of a naïve or memory T cell.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Anti–PD-1/PD-L1–mediated acquired resistance is dependent on CD38-generated adenosine in the tumor microenvironment. Anti–PD-1/PD-L1–mediated acquired.

Low initial levels of CD4+ Tregs, proliferating CD8+, and Granzyme B+ CD8+ T cells and high posttreatment tumor MHC class II expression predict better.

Presentation transcript:

BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment into the MHC-I presentation pathway, a process called cross-presentation. BATF3-expressing professional antigen-presenting cells (DC) are able to cross-present tumor antigen (TA) by channeling material taken up from their environment into the MHC-I presentation pathway, a process called cross-presentation. Cross-presented tumor antigens are recognized by CD8+ CTLs via their tumor antigen specific T-cell receptors (TCR). CTL activation can be enhanced with monoclonal antibodies (mAb) that stimulate activatory receptors (e.g., αCD137 mAb) and/or block inhibitory receptors (e.g., αPD-1 mAb). These treatments induce potent CTL responses capable of destroying cancer cells, resulting in tumor regression and/or disease stabilization. Céline Robert-Tissot, and Daniel E. Speiser Cancer Discov 2016;6:17-19 ©2016 by American Association for Cancer Research